龙沙股价因销售额和盈利增长而上涨。 Lonza Shares Rise on Sales, Earnings Beat.

瑞士制药公司 Lonza 公布 2023 年销售额增长 10.9%，达到 67 亿瑞士法郎（69 亿美元）。 Lonza, a Swiss pharmaceutical company, reported a 10.9% increase in sales for 2023, reaching CHF 6.7 billion ($6.9 billion). 所报告的增长是由 Lonza 的生物制剂和小分子部门推动的。 The reported growth was driven by Lonza's Biologics and Small Molecules divisions. Lonza 继续实施增长投资战略，资本支出占销售额的 25%。 Lonza continued its growth investment strategy with a 25% CAPEX of sales. 到 2024 年，该公司计划将资本支出维持在销售额的 25%，CER 销售额增长持平，核心 EBITDA 利润率保持在 20% 以上。 For 2024, the company plans to maintain its CAPEX at 25% of sales, with flat CER sales growth and a CORE EBITDA margin in the high twenties. Lonza 董事长 Albert Baehny 计划在 2024 年 5 月的年度股东大会后辞职，并提名 Jean-Marc Huet 作为其继任者。 Lonza's Chairman, Albert Baehny, plans to step down after the annual general meeting in May 2024, with Jean-Marc Huet proposed as his successor.